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Abstract
IMPORTANCE Increasing BRCA1 and BRCA2 (collectively termed herein as BRCA) gene testing is
required to improve cancer management and prevent BRCA-related cancers.
OBJECTIVE To evaluate mainstream genetic testing using cancer-based criteria in patients
with cancer.
DESIGN, SETTING, ANDPARTICIPANTS A quality improvement study and cost-effectiveness
analysis of different BRCA testing selection criteria and access procedures to evaluate feasibility,
acceptability, andmutation detection performance was conducted at the Royal Marsden National
Health Service Foundation Trust as part of the Mainstreaming Cancer Genetics (MCG) Programme.
Participants included 1184 patients with cancer who were undergoing genetic testing between
September 1, 2013, and February 28, 2017.
MAINOUTCOMESANDMEASURES Mutation rates, quality-adjusted life-years (QALYs), and
incremental cost-effectiveness ratios were the primary outcomes.
RESULTS Of the 1184 patients (1158 women [97.8%]) meeting simple cancer-based criteria, 117 had
a BRCAmutation (9.9%). Themutation rate was similar in retrospective United Kingdom (10.2% [235
of 2294]) and prospective Malaysian (9.7% [103 of 1061]) breast cancer studies. If traditional family
history criteria had been used, more than 50% of themutation-positive individuals would have been
missed. Of the 117 mutation-positive individuals, 115 people (98.3%) attended their genetics
appointment and cascade to relatives is underway in all appropriate families (85 of 85). Combining
with the equivalent ovarian cancer study provides 5 simple cancer-based criteria for BRCA testing
with a 10%mutation rate: (1) ovarian cancer; (2) breast cancer diagnosed when patients are 45 years
or younger; (3) 2 primary breast cancers, both diagnosedwhen patients are 60 years or younger; (4)
triple-negative breast cancer; and (5) male breast cancer. A sixth criterion—breast cancer plus a
parent, sibling, or child with any of the other criteria—can be added to address family history. Criteria
1 through 5 are considered theMCG criteria, and criteria 1 through 6 are considered theMCGplus
criteria. Testing using MCG or MCGplus criteria is cost-effective with cost-effectiveness ratios of
$1330 per discounted QALYs and $1225 per discounted QALYs, respectively, and appears to lead to
cancer andmortality reductions (MCG: 804 cancers, 161 deaths; MCGplus: 1020 cancers, 204 deaths
per year over 50 years). Use ofMCG orMCGplus criteriamight allow detection of all BRCAmutations
in patients with breast cancer in the United Kingdom through testing one-third of patients. Feedback
questionnaires from 259 patients and 23 cancer teammembers (12 oncologists, 8 surgeons, and 3
nurse specialists) showed acceptability of the process with 100% of patients pleased they had
genetic testing and 100%of cancer teammembers confident to approve patients for genetic testing.
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Key Points
Question How can BRCA1 and BRCA2
gene testing in patients with cancer be
increased?
Findings In this quality improvement
study of 1184 individuals, 5 cancer-based
criteria with a 10%mutation detection
rate were used by the cancer team to
approve genetic testing for patients
with cancer.
Meaning Mainstreaming genetic
testing using simple, cancer-based





Author affiliations and article information are
listed at the end of this article.
Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2019;2(5):e194428. doi:10.1001/jamanetworkopen.2019.4428 (Reprinted) May 24, 2019 1/13
Downloaded From: https://jamanetwork.com/ by a Institute of Cancer Research UK User  on 06/08/2020
Abstract (continued)
Use of MCGplus criteria also appeared to be time and resource efficient, requiring 95% fewer genetic
consultations than the traditional process.
CONCLUSIONS ANDRELEVANCE This study suggests that mainstream testing using simple,
cancer-based criteria might be able to efficiently deliver consistent, cost-effective, patient-centered
BRCA testing.
JAMA Network Open. 2019;2(5):e194428. doi:10.1001/jamanetworkopen.2019.4428
Introduction
Germline mutations in BRCA1 or BRCA2 (collectively termed herein as BRCA) contribute
to approximately 12% to 15% of ovarian cancer and approximately 3% to 5%of breast cancer inmost
populations.1-3 Identifying BRCAmutations can deliver substantial benefits in cancer management
and cancer prevention.1,4,5 Patients with cancer with BRCA mutations are at increased risk of a
second cancer, andmany choose to have bilateral mastectomy and/or salpingo-oophorectomy to
mitigate this risk.1,4 Furthermore, specific therapeutic options for cancers driven by BRCAmutations
are increasingly available.1,5 Identification of a BRCAmutation also provides opportunities for
relatives to access improved cancer risk information, screening, and risk-reducing interventions, and
it is a cost-effective cancer prevention strategy.4,6-11
When the BRCA genes were discovered, the time and cost of testing precluded routine
integration into the cancer diagnostic pathway. Instead, family history (FH) of cancer was used to
identify individuals most likely to have a BRCAmutation, with many countries using a 10% chance of
a BRCAmutation as the test access threshold.12-14 However, implementation of BRCA testing has
been impeded by the complexity of FH criteria and the limited FH information typically available in
clinical medicine.15-17 These impediments have led to inappropriate and inconsistent testing.18-22
Furthermore, many patients with cancer with BRCA mutations are not tested because they do not
fulfill FH criteria.23,24
These problems have led to systematic underuse and inappropriate use of BRCA testing over
the past 2 decades, with consequent lost opportunities for improved cancermanagement and cancer
prevention.14-26 A recent US study estimated that only 20% of eligible individuals are being offered
testing, with more than amillion eligible individuals not having testing between 2000 and 2010.27 It
is further estimated that only 30%of patients with breast cancer and 10%of unaffected individuals
with BRCA mutations in the United States have been identified.28 These challenges and outcomes
have been similar in many other countries.14-26
To improve BRCA testing, the Mainstreaming Cancer Genetics (MCG) Programme has been
developing simplified eligibility criteria and testing access processes.29 Ovarian cancer was
addressed first, simplifying eligibility to all womenwith epithelial ovarian cancer, as the BRCA
mutation rate is more than 10%within this group. Amainstream test access model was validated in
which patients with ovarian cancer were directly approved for BRCA testing by their cancer team,
with patients who were BRCAmutation-positive rather than all patients having an appointment for
genetics consultation. The mainstreammodel has proved to be popular, efficient, and cost-effective
and more than 1000 patients with ovarian cancer have had BRCA testing through the mainstream
access model in the Royal Marsden National Health Service Foundation Trust.7 Many other centers
have adopted similar processes, with comparable positive results.30-34 Herein we report on the
development and evaluation of simple, cancer-based eligibility criteria for use in mainstream genetic
testing in patients with breast cancer.
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Methods
MCG-Breast
TheMCG Programmewas a quality improvement program aimed at making BRCA genetic testing
routine for appropriate patients with cancer (eAppendix 1 in the Supplement). There were 2
subprojects: the first was led by the gynecology-oncology team and has been published29 and the
second was the equivalent breast team project, MCG-breast. We used structured literature review,
international guidelines, and real-world evidence to determine 5 simple, cancer-based criteria
estimated to give an approximate 10%mutation detection rate in patients with breast cancer
(eFigure 1 in the Supplement). The Royal Marsden/Institute of Cancer Research/National Institute for
Health Research Specialist Biomedical Research Centre ReviewBoard approved the study. Informed
written consent was obtained from all participants; they did not receive financial compensation. This
study followed the Standards for Quality Improvement Reporting Excellence (SQUIRE) reporting
guideline for quality improvement studies.
Patient Populations
TheMCG-breast study ran for 3.5 years, between September 1, 2013, and February 28, 2017. A total
of 1184 patients with breast cancer received genetic testing through MCG-breast during this period.
Nine breast cancer predisposition genes (BRCA1 [OMIM 113705],BRCA2 [OMIM600185], PALB2 [OMIM
610355], TP53 [OMIM 191170], PTEN [OMIM 601728], STK11 [OMIM 602216], CDH1 [OMIM 192090],
ATM [OMIM 607585], and CHEK2 [OMIM 604373]) were tested using the TruSight Cancer Panel
(IIlumina).
While MCG-breast was running, 182 patients with breast cancer underwent testing through the
genetics department because, although the proband did not fulfill anMCG-breast criterion, their FH
made them eligible as they had aManchester Scoring System (MSS) score of 15 or higher (eFigure 2 in
the Supplement). These individuals are called the FH series.
We also used data from 2294 patients from the Breast andOvarian Cancer Susceptibility (BOCS)
study, a retrospective UK study of familial breast cancer, and 2575 patients from theMalaysia-Breast
Cancer genetics Study (BCGS),35 a prospective Malaysian study of patients with cancer unselected
for age or FH, to evaluate the mutation detection rates of the MCG-breast criteria. We used these
patient populations to compare MCG-breast criteria with 3 widely used systems for determining
BRCA testing eligibility: the MSS1,36 Breast and Ovarian Analysis of Disease Incidence and Cancer
Estimation Algorithm (BOADICEA),37 and the National Comprehensive Cancer Network (NCCN)
Guidelines.38
Patient and Cancer TeamAcceptability
We evaluated patient and cancer team acceptability of themainstream process using similar
questionnaires to the equivalent ovarian cancer programme.29We initiated the patient feedback
once 250 had been consented by the cancer team, sending questionnaires to 259 participants, of
whom 129 replied (113 BRCAmutation-negative and 16 BRCAmutation-positive). Twenty-three
members of the cancer team completed the cancer team feedback questionnaire, including 12
oncologists, 8 surgeons and 3 nurse specialists. The questionnaire and results are detailed in eTable 2
and eTable 3 in the Supplement.
Cost-effectiveness Analyses
We performed a cost-effectiveness analysis using themodel in Eccleston et al7 that was adapted for
breast cancer. A patient-level simulation with a lifetime time horizon was constructed in Microsoft
Excel (Microsoft Corp). In the model, an index population is compared for testing and no testing
scenarios, patients are offered BRCA testing using mainstream testing, and cascade testing to
unaffected family members is included. The analysis was conducted according to the Consolidated
Health Economic Evaluation Reporting Standards (CHEERS) guideline.
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The principal outcomewas the cost per quality-adjusted life-year for each individual and
aggregated to provide an incremental cost-effectiveness ratio. Other outcomes included total and
disaggregated costs and clinical events, such as the number of new cancer cases prevented and the
number of lives saved over a 50-year horizon. We also performed a probabilistic sensitivity analysis
and constructed a multiple cost-effectiveness acceptability curve. Additional details on the methods
are presented in eAppendix 2 in the Supplement.
Results
MCG-Breast
A total of 1184 individuals with breast cancer (1158 women [97.8%] and 26men [2.2%]), underwent
BRCA testing because they fulfilled 1 or more of the eligibility criteria. Of these, 117 patients had a
BRCAmutation, giving an overall mutation rate of 9.9% (Table 1; eTable 1 in the Supplement). The
mutation rate of each criterion exceeded 10%. Most individuals met only 1 criterion (926 [78.2%]),
with 246 (20.8%)meeting 2 criteria and 12 (0.1%) meeting 3 criteria, with mutation rates of 7.7% (71
of 926), 16.3% (40 of 246), and 50.0% (6 of 12), respectively (Table 1).
Of 117 mutation-positive individuals, 115 patients (98.3%) attended their genetics appointment.
Of the 2missing individuals, 1 declined her appointment and chemotherapy and subsequently died,
and the other initially declined her appointment but then recontacted the genetics department.
Cascade of information to relatives is underway in 85 families, was not relevant in 16 families, and is
of unknown status in 16 families outside our catchment area. We surveyed 259 patients to evaluate
acceptability of the process, of whom 129 replied (eTable 2 in the Supplement). Acceptability was
Table 1. Cancers and BRCAMutation Status inMCG-Breast, BOCS, andMalaysia-BCGSa
Cancer Status Total Cases, No. (%) With a BRCA Mutation, No. (%)
MCG-Breast
All cases 1184 117 (9.9)
BC diagnosed when patient is ≤45 y 740 (62.5) 80 (10.8)
2 Primary BCs, both diagnosed when patient is ≤60 y 229 (19.3) 32 (14.0)
Triple-negative BC 423 (35.7) 44 (10.4)
BC+OC 36 (3.0) 10 (27.8)
Male BC 26 (2.2) 3 (11.5)
Criteria met
1 926 (78.2) 71 (7.7)
2 246 (20.8) 40 (16.3)
3 12 (0.1) 6 (50.0)
BOCS
All cases 2294 235 (10.2)
BC diagnosed when patient is ≤45 y 1630 (71.1) 181 (11.1))
2 Primary BCs, both diagnosed when patient is ≤60 y 510 (22.2) 54 (10.6)
Triple-negative BC 1073 (46.8) 127 (11.8)
Criteria met
1 1464 (63.8) 128 (8.7)
2 741 (32.3) 87 (11.7)
3 89 (38.8) 20 (22.5)
Malaysia-BCGS
All cases 1061 103 (9.7)
BC diagnosed when patient is ≤45 y 812 (76.5) 82 (10.1)
2 Primary BCs, both diagnosed when patient is ≤60 y 105 (9.9) 18 (17.1)
Triple-negative BC 321 (30.3) 41 (12.8)
BC+OC 17 (1.6) 3 (17.6)
Abbreviations: BC, breast cancer; BCGS; Breast Cancer
Genetic Study; BOCS, Breast and Ovarian Cancer
Susceptibility; MCG, Mainstreaming Cancer Genetics;
OC, ovarian cancer.
a BRCA includes BRCA1 and BRCA2.
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high, with 100% (128 of 128) pleased that they had genetic testing and 96.1% (124 of 129) happy that
testing was done by their cancer team.
The cancer team acceptability of the process was also high. All 23 teammembers reported
feeling confident to approve patients for BRCA testing during the cancer clinic consultation and
believed that the process worked well (eTable 3 in the Supplement).
Evaluation of Testing Criteria in Other Data Sets
To further evaluate the testing eligibility criteria, we used data from 2294 participants in the BOCS
Study for whom information to determine eligibility for criteria 1 through 3 was available. Of these,
235 patients (10.2%) had a BRCAmutation and each criterion also met the 10% threshold (Table 1).
To evaluate the criteria in a different population, we used data from theMalaysia-BCGS study, a
prospective study of 2575 unselectedwomenwith breast cancer .35 Of these, 1061 patients (41.2%)
were eligible for testing, of whom 103 women (9.7%) had a BRCA mutation (Table 1). Male breast
cancer was not included in the study and the presence of exon deletion/duplication mutations was
not tested. Consistent with the MCG-breast and BOCS data, the mutation detection rate in each
category was approximately 10% (Table 1).
ComparisonWithOther Eligibility Criteria
We evaluated which of the 117 mutation-positive probands would have been eligible for testing using
the MSS1,36 BOADICEA37 or the NCCN criteria.38 Fifty-five probands (47.0%) had an MSS1 score of
15 or greater and 37 probands (31.6%) had a 10% or greater mutation probability by BOADICEA. One
hundred six patients (90.6%)met the NCCN criteria, of whom 103 patients (88.0%) were eligible
through their personal cancer history (eTable 1 in the Supplement).
MCGCriteria
We combined the results of the MCG-breast and the equivalent gynecology-oncology study to
develop universal testing criteria that could be used to determine eligibility of any patient with breast
or ovarian cancer.We call these theMCG criteria (Figure). TheMCG-breast criterion of awomanwith
breast and ovarian cancer became redundant because anywomanwith epithelial ovarian cancer has
a greater than 10% chance of having a BRCA mutation.29 Thus, the MCG criteria are (1) ovarian
cancer, (2) breast cancer diagnosed when patients are 45 years or younger, (3) 2 primary breast
cancers diagnosed when patients are 60 years or younger, (4) triple-negative breast cancer, and (5)
breast cancer in men (Figure).
ComparisonWith FH-Based Testing
During the study period, an additional 182 patients with breast cancer were tested through the
genetics department. These patients did not fulfill MCG-breast criteria, but their FHmade them
eligible for testing because their MSS score was 15 or higher (eFigure 2 in the Supplement). Ten
patients (5.5%) in this FH series had a BRCAmutation (eTable 4 in the Supplement). All 10 patients
had a relative eligible for testing using the MCG criteria, and in 9 families an eligible relative was
diagnosedwith cancer before the proband (eTable 4 in the Supplement). A total of 151 of 182 patients
(83.0%) in the FH series had an eligible relative and 86 individuals (47.3%) had an eligible first-
degree relative.
Figure. Mainstreaming Cancer Genetics (MCG) Criteria
1. Ovarian cancer
6. Breast cancer plus parent, sibling, or child with any of the above criteria
2. Breast cancer in patient diagnosed ≤45 y
3. Two primary breast cancers, both diagnosed in patient ≤60 y
4. Triple-negative breast cancer
5. Male breast cancer
MCG
MCGplus
MCG includes criteria 1 through 5; MCGplus includes
criteria 1 through 6. Ovarian cancer indicates epithelial
ovarian cancer.
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TheMCG-breast and FH series samples also underwent analysis of 7 additional breast cancer
predisposition genes: 5 rare, higher penetrance predisposition genes (PALB2, TP53, CDH1, PTEN, and
STK11) and 2more common, lower penetrance predisposition genes (ATM and CHEK2).39 One
individual (0.05%) in the FH series had amutation in a higher penetrance non-BRCA predisposition
gene compared with 24 patients (2.0%) in the MCG-breast group. In total, 9 patients (4.9%) in the
FH series and 51 patients (4.3%) in the MCG-breast group had mutations in non-BRCA cancer
predisposition genes (eTable 5 in the Supplement).
We next considered all 1366 individuals tested during the study period through theMCG-breast
or FH series, of whom 127 patients (9.3%) had a BRCAmutation. The BRCAmutation detection rate
using the different eligibility criteria are given in Table 2. TheMCG and NCCN criteria performed best,
with 92.1% (n = 117) and 91.3% (n = 116) mutation detection rates, respectively.
We also considered whether it were possible to extend the simple cancer-based criteria to
encompass themissedmutations detected through the FH series. Six of 10 FH-series mutations
(60.0%) were in patients with breast cancer with first-degree relatives whowould have been eligible
for testing.We therefore added a sixth category, which is breast cancer and a parent, sibling, or child
(ie, a first-degree relative) with any of the other criteria. Criteria 1 through 5 are considered theMCG
criteria and 1 through 6 are considered the MCGplus criteria (Figure). Applying the MCGplus criteria
to the 1366 (MCG-breast plus FH series) individuals leads to an extra 86 people being eligible for
testing, compared with theMCG criteria, and detection of an extra 6mutations. Overall, MCGplus
criteria detected 123 of 127 mutations (96.7%) and retained an overall mutation rate of 9.7% (123 of
1270) (Table 2).
Table 2. Detection of BRCAMutation by Different Eligibility Criteriaa
Eligibility Criteria Total No. of BRCA Mutation Carriers
BRCA Mutation Carriers Eligible
for Testing, No. (%)
All BRCA Mutation Carriers
MCGplus 127 123 (96.9)
MCG 127 117 (92.1)
NCCN
All criteria 127 116 (91.3)
Personal cancer criteria 127 106 (83.5)
MSS score ≥15 127 65 (51.2)
BOADICEA ≥10 127 39 (30.7)
BRCA Mutation Carriers Identified
In MCG-breast
MCGplus 117 117 (100)
MCG 117 117 (100)
NCCN
All criteria 117 106 (91.0)
Personal cancer criteria 117 103 (88.0)
MSS score ≥15 117 55 (47.0)
BOADICEA ≥10 117 37 (31.6)
In FH-series
MCGplus 10 6 (60.0)
MCG 10 0
NCCN
All criteria 10 10 (100)
Personal cancer criteria 10 0
MSS score ≥15 10 10 (100)
BOADICEA ≥10 10 2 (20.0)
Abbreviations: BOADICEA, Breast and Ovarian
Analysis of Disease Incidence and Cancer Estimation
Algorithm; FH, family history; MCG, Mainstreaming
Cancer Genetics; MSS, Manchester Scoring System;
NCCN, National Comprehensive Cancer Network.
a BRCA includes BRCA1 and BRCA2.
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Cost-effectiveness
We performed a cost-effectiveness analysis using the ovarian cancer cost-effectiveness model
previously described, adapted for breast cancer.7 We compared implementation of BRCA testing
using the mainstream process and the MCG or MCGplus criteria with no testing. Both the MCG and
MCGplus criteria were cost-effective with cost-effectiveness ratios of $1330 per discounted QALYs
(Table 3) and $1225 per discounted QALYs (Table 4), respectively. Multiple cost-effectiveness
acceptability curves showed that BRCA testing withMCG orMCGplus criteria had a greater than 99%
probability of being cost-effective at a willingness-to-pay threshold of $26 184 per quality-adjusted
life-year.With use of theMCG criteria, themodel estimates that 804 cancers and 161 deathswould be
prevented per year of testing over the subsequent 50 years. With use of theMCGplus criteria, 1020
cancers and 204 deaths are estimated to be prevented per year over 50 years.
Genetic Testing and Consult Requirements
Determining who is eligible for cancer predisposition gene testing based on personal history rather
than FH allows one to better estimate testing and resource requirements. To exemplify this, we
considered the UK outcome of implementing themainstream testing model with theMCG or
MCGplus criteria. Approximately 55000 breast cancer cases and 7000 ovarian cancer cases are
diagnosed in the United Kingdom each year. We estimate that approximately 20000 individuals
would be eligible for testing using theMCG criteria and approximately 25000would be eligible
using theMCGplus criteria (eTable 6 in the Supplement). These numbers would lead to the
identification of 2000 (MCG) or 2500 (MCGplus) BRCAmutations each year, given themutation
detection rate of approximately 10%. Approximately 12% of ovarian cancer and 3% of breast cancer
diagnoses occur in BRCAmutation carriers, which is 2500 per year (840 ovarian cancers and 1650
breast cancers).2,3 Hence, using the MCGplus criteria theoretically allows one to identify all of the
BRCAmutations in patients with breast cancer through testing of only a third of the patients. Using
the mainstream access model also leads to substantial reduction in testing time and genetic
consultation requirements (eFigure 3 in the Supplement). In the traditional access model, everyone
has input from the genetics department before and after testing; thus, 50000 consultations would
be required if theMCGplus criteria were used. In themainstreammodel, the discussions before and
after the test are undertaken by the cancer team during existing appointments. The 2500 BRCA
mutation-positive individuals additionally have a genetics department appointment—a 95%
reduction in genetic consultation requirements. The posttest cancer and genetic management for
the BRCAmutation-positive individuals and their relatives is the same in bothmodels (eFigure 3 in
the Supplement). Themainstream access model also results in approximately 85% (4 vs 25 weeks in
Table 3. Cost-effectiveness ofMCG Criteria
Outcomes No Testing Testing Difference
Deaths, No. 4404 4243 −161
OC cases, No. 3047 2545 −502
BC cases, No. 989 687 −302
Total costs, $ 172 525 741 175 259 610 2 733 869
Discounted QALYs 57 691 59 746 2055
Abbreviations: BC, breast cancer; MCG, Mainstreaming
Cancer Genetics; OC, ovarian cancer; QALY, quality-
adjusted life-year.
Table 4. Cost-effectiveness ofMCGplus Criteria
Outcomes No Testing Testing Difference
Deaths, No. 5457 5253 −204
OC cases, No. 3763 3116 −647
BC cases, No. 1202 829 −373
Total costs, $ 190 223 417 193 587 091 3 363 675
Discounted QALYs 71 046 73 792 2746
Abbreviations: BC, breast cancer; MCG, Mainstreaming
Cancer Genetics; OC, ovarian cancer; QALY, quality-
adjusted life-year.
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the United Kingdom) reduction in time to test result, compared with the traditional access model
(eFigure 3 in the Supplement).
Discussion
In this study of 1184 individuals, we estimate that simple, cancer-based criteria may identify patients
with breast cancer eligible for genetic testing at an approximate 10%BRCAmutation rate threshold.
Our results are supported by data from 2294 patients from a retrospective UK study of familial breast
cancer and 2575 patients from a prospective Malaysian study of unselected breast cancer.
Integrating these results with our equivalent study in ovarian cancer leads to 5 simple MCG
criteria that can be used to determine which patients with breast or ovarian cancer should be offered
genetic testing. The simplicity of the criteria makes it possible to readily and consistently determine
who is eligible for testing. In turn, a mainstream testingmodel may be usedwhereby the cancer team
directly performs testing instead of referring patients to the genetics department. Patients and
cancer teammembers expressed satisfaction in this process, and it also appears to be time- and cost-
efficient. In particular, mainstream testing reduces genetic consultation requirements by
approximately 95%, as only the 10%mutation-positive individuals have genetic input after the test,
comparedwith the traditionalmodel in which all patients have genetic input before and after testing.
It is recognized that, in most countries, a shortage of genetic counselors precludes offering pretest
and posttest counseling to all eligible patients with cancer in a timely fashion.40,41 This limitation has
led to ad hoc, nonvalidated testingwithout genetic counseling.41With the cost of testing decreasing
and the therapeutic implications of testing increasing, it is inevitable that testing without prior
genetic counselor input will expand. Furthermore, tumor (somatic) genetic testing, which is initiated
by the cancer team, is rapidly expanding and it is likely that germline and tumor genetic testing will
converge over the next 5 years. We therefore believe it is preferable to explicitly institute germline
genetic testing by the cancer team in close collaboration with the genetics department, as we have
done herein. This cooperation ensures that the cancer team will give appropriate information before
testing and that patients will receive genetic inputwhen required. It is reassuring that we, and others,
have found that patients with cancer are supportive of this testing model.29-34
The cancer-based criteria performed better than the FH-basedMSS and BOADICEA, both of
which would havemissedmore than 50% of themutations. This finding is consistent with other
studies showing that FH is a suboptimal selection method for identifying patients with cancer who
have BRCA mutations.23,24,29 The mutation rate of patients in the FH series who met FH-based
criteria but did not meet MCG-breast criteria was only 5.5%. This low level is to be expected; it is
inevitable that themutation rate of FH-based criteria will be reduced if one excludes patients eligible
through their cancer status. Historically, such evaluations have taken the reverse approach; they have
evaluated themutation rate in patients with cancer not eligible by FH-based criteria.12 Given that
cancer-based criteria are easier and faster to use, we believe prioritizing cancer-based criteria and
adding FH-based criteria, if required, is the preferable approach. Moreover, 151 of 182 patients
(83.0%) in the FH series had a relative eligible for testing by theMCG criteria, including all of the
mutation-positive individuals. This finding suggests that systematic deployment of theMCG criteria
would, in time, detect almost all of the mutations currently identified by FH-based criteria as well as
manymutations that FH-based criteria miss. Cancer-based criteria also make it easier to estimate
and evaluate testing service requirements and performance than when using FH-based criteria, as
we demonstrate for the United Kingdom. Use of the cancer-based criteria should facilitate the
improvement in BRCA testing delivery that many studies have shown is required.14-26
For countries without a legacy of FH-based testing or those in which FH discussions can deter
testing, we believe the 5MCG criteria offer a simple, useful way to deliver genetic testing to patients
with breast and ovarian cancer. For countries that have used FH-based selection criteria for many
years, this change may be too radical. To address this issue, we developed MCGplus criteria, which
retain the simplicity and mutation rate of the MCG criteria and add a sixth criterion of a patient with
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breast cancer who has a parent, sibling, or child meeting the MCG criteria. In due course, this sixth
criterion should become obsolete because the eligible relative will have been tested during their
cancer diagnosis. In our center we have been using theMCGplus criteria in genetics and oncology
since November 2017, and this has been well received (eFigure 4 in the Supplement).
In recent years the NCCN has expanded personal cancer-based criteria, which has led to
improvedmutation detection. The NCCN criteria performed similarly to theMCG criteria but are
more complex, as both cancer-based and FH-based criteria are now included. This complexity makes
use of the NCCN guidelines time consuming, impeding widespread adherence.16,19,21,35 There are
strong similarities between theMCG and NCCN cancer-based criteria. A key difference is that all
patients with triple-negative breast cancer are eligible byMCG criteria, but only those younger than
60 years are eligible by the NCCN. Ten of 44 mutation-positive women (22.7%) with triple-negative
breast cancer in MCG-breast were diagnosed when they were older than 60 years. Moreover, the
mutation rate in triple-negative breast cancer at any age in the MCG-breast, BOCS, and Malaysia-
BCGS data was greater than 10%, and this finding is consistent with other studies.12,42,43 It is
noteworthy that 106 of 116mutations (91.4%) detected by the NCCN criteria were in patients eligible
for testing due solely to their cancer history, althoughmany also fulfilled FH criteria. This finding
suggests that there may be redundancy in the NCCN cancer-based and FH-based criteria that could
be streamlined.
Using MCG or MCGplus criteria is cost-effective and appears to result in meaningful cancer and
mortality reductions. BRCA testing using many different criteria and testing processes has been
shown to be cost-effective.4,6-11 The combined economic benefit and increasing clinical utility of
testing appear to provide a strong argument for relaxing themutation threshold and expanding
testing tomore patients with breast cancer. Changing the age threshold for breast cancer to 50 years
or younger or 60 years or younger and removingMCG criterion 2 would be the logical expansions
and simplifications of the MCG criteria. Ultimately, offering testing to all patients with breast cancer
will likely occur. However, currently, most centers have limited resources theymust use for testing at
a specified mutation detection threshold.
Limitations
The study has limitations. The cost-effectiveness analysis we performed compared testing with no
testing. When we initiated the study, no germline genetic testing in oncology was performed in the
United Kingdom, so testing vs no testing was considered the most appropriate comparison.
Furthermore, a major aspiration of theMCG Programmewas to provide data and resources that
could be used by themany centers and countries that do not yet offer BRCA testing. However, for
some centers, for example, thosewith surplus genetic resources that can be used in oncology, amore
appropriate comparison would be between theMCG criteria and FH-based criteria.
Concurrent testing of other cancer predisposition genes in addition to the BRCA genes is being
increasingly performed.44 We suggest that the mainstream testing process can be readily adapted
for multigene testing; in our study, it led to an extra 51 (40% increase) posttest genetic consultations
for patients with mutations in non-BRCA genes. However, we did not evaluate the performance of
MCG criteria for non-BRCA genes. We believe that MCG criteria are likely to perform at least as well as
other criteria becausemore eligible patients receive testing using theMCG criteria andmainstream
testing process.45,46 TheMCG criteria also do not address BRCA testing in patients with cancers other
than breast or ovarian. To our knowledge, there is no evidence that personal history of cancers other
than breast or ovarian would meet a 10%mutation detection threshold.
Conclusions
It is well known that underuse and inappropriate use of genetic testing in patients with cancer is
impeding cancer management and prevention.14-26 Herein, we presented a streamlined genetic
testing process based on short, simple eligibility criteria that can be used by the cancer team.We
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suggest that mainstreaming testing using these criteria may be an efficient way to deploy limited
resources in a consistent, transparent, equitable, cost-effective, patient-centeredmanner.
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